About NeuroSense Therapeutics Ltd.
https://www.neurosense-tx.comNeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for debilitating neurodegenerative diseases in Israel. Its lead product candidate is PrimeC, a novel oral formulation for the treatment of amyotrophic lateral sclerosis.
CEO
Alon Ben-Noon
Compensation Summary
(Year )
Ratings Snapshot
Rating : C-
Price Target
Institutional Ownership
EMPERY ASSET MANAGEMENT, LP
Shares:160K
Value:$56K
CLEAR STREET GROUP INC.
Shares:63.69K
Value:$22.29K
CLEAR STREET LLC
Shares:63.69K
Value:$22.29K
Summary
Showing Top 3 of 5
About NeuroSense Therapeutics Ltd.
https://www.neurosense-tx.comNeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for debilitating neurodegenerative diseases in Israel. Its lead product candidate is PrimeC, a novel oral formulation for the treatment of amyotrophic lateral sclerosis.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $0 | $2.35M | $-2.35M | 0% | $-0.09 | $-2.34M |
| Q1-2025 | $0 | $2.35M ▲ | $-2.35M ▼ | 0% | $-0.09 ▼ | $-2.34M ▼ |
| Q4-2024 | $0 | $1.77M ▼ | $-1.8M ▲ | 0% | $-0.08 ▲ | $-1.77M ▲ |
| Q3-2024 | $0 | $2.11M ▼ | $-2.15M ▼ | 0% | $-0.11 ▼ | $-2.1M ▲ |
| Q2-2024 | $0 | $3.03M | $-857K | 0% | $-0.05 | $-3.02M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $666K | $1.68M | $2.2M | $-519K |
| Q1-2025 | $666K ▼ | $1.68M ▼ | $2.2M ▲ | $-519K ▼ |
| Q4-2024 | $3.38M ▲ | $4.58M ▲ | $1.99M ▼ | $2.58M ▲ |
| Q3-2024 | $344K ▼ | $984K ▼ | $3.8M ▲ | $-2.82M ▼ |
| Q2-2024 | $1.24M | $1.84M | $3.54M | $-1.7M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-2.35K | $-2K ▼ | $-6.5 ▼ | $650.5 ▲ | $-1.36K ▼ | $-2K ▼ |
| Q1-2025 | $-2.35K ▼ | $0 | $0 | $0 | $0 | $0 |
| Q4-2024 | $-1.8K ▲ | $0 | $0 | $0 | $0 | $0 |
| Q3-2024 | $-2.15K ▼ | $0 | $0 | $0 | $0 | $0 |
| Q2-2024 | $-857 | $0 | $0 | $0 | $0 | $0 |
CEO
Alon Ben-Noon
Compensation Summary
(Year )
Ratings Snapshot
Rating : C-
Price Target
Institutional Ownership
EMPERY ASSET MANAGEMENT, LP
Shares:160K
Value:$56K
CLEAR STREET GROUP INC.
Shares:63.69K
Value:$22.29K
CLEAR STREET LLC
Shares:63.69K
Value:$22.29K
Summary
Showing Top 3 of 5